Neophyr (Nitric Oxide)

Nitric oxide delivered by Neophyr diffuses into the pulmonary vasculature, where it activates soluble guanylate cyclase. This raises intracellular cGMP, causing smooth‑muscle relaxation and selective vasodilation of pulmonary arteries, which enhances ventilation‑perfusion matching without systemic blood pressure effects.

The dose of Neophyr is individualized. A qualified prescriber determines the appropriate concentration and duration of inhalation based on the patient’s clinical condition, response to therapy, and monitoring results.

Neophyr should be used in pregnancy only when the potential benefit outweighs any risk to the fetus. Caution is advised during breastfeeding because nitric oxide may be transferred to the infant; a healthcare professional should evaluate the risk‑benefit ratio.

To order Neophyr, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Neophyr’s nitric oxide provides rapid, selective pulmonary vasodilation, whereas inhaled prostacyclin analogues act through a different pathway and may have broader systemic effects. Nitric oxide’s short half‑life allows precise titration, but it requires specialized delivery equipment and monitoring for methemoglobinemia.

Neophyr should be stored at ambient temperature, protected from moisture and direct light, and kept in its original packaging. The product must be used with the recommended delivery system and handled according to the manufacturer’s instructions to maintain stability.

Neophyr is administered by inhalation using a calibrated delivery system that mixes the nitric oxide gas with the patient’s inspiratory flow. The device allows precise control of concentration and duration, and continuous monitoring of oxygenation and methemoglobin levels during therapy.

The most serious risks include severe hypotension, rebound pulmonary hypertension after abrupt discontinuation, high‑level methemoglobinemia, and nitrogen dioxide toxicity from oxidation of nitric oxide. Prompt recognition and monitoring are essential to mitigate these complications.

Neophyr is contraindicated in patients with known hypersensitivity to nitric oxide, those with severe methemoglobinemia, or individuals with significant anemia where oxygen‑carrying capacity is already compromised. Caution is also advised for patients with renal impairment or those receiving phosphodiesterase inhibitors.